Amryt in-licenses novel gene therapy platform from UCD – PharmaTimes
PharmaTimes |
Amryt in-licenses novel gene therapy platform from UCD
PharmaTimes UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile … |
